Clinical Trials
16 trialsNCT07617584 2026-06-01
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Ss. Cyril and Methodius University of Skopje
Phase NA Not yet recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06054178 2026-05-20
Identification of Nerves Using Fluorescein Sodium
Stanford University
Phase 2 Completed
NCT07600580 2026-05-20
The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response
University Hospital Dubrava
Phase 4 Active not recruiting
NCT07575243 2026-05-12
Thyroidectomy-specific Enhanced Recovery After Surgery (ERAS) Protocol
Assiut University
Completed
NCT05265091 2026-05-08
A Study of KL590586 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2 Active not recruiting
NCT06730321 2026-05-07
Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)
Shanghai 6th People's Hospital
Recruiting
NCT06738888 2026-05-07
Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy
Shanghai 6th People's Hospital
Recruiting
NCT05660954 2026-05-04
CABOTHYROID
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04913285 2026-04-27
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
Phase 1 Active not recruiting
NCT05733013 2026-04-27
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Recruiting
NCT07543887 2026-04-22
EECRTKI
University of Pisa
Completed
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07488585 2026-04-07
THYMAL 01
Sound Blade Medical Inc.
Phase NA Not yet recruiting
NCT04615988 2026-03-27
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Icahn School of Medicine at Mount Sinai
Recruiting
NCT05059470 2026-03-23
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated